Ebola Transmission Rate Slows In DRC, But WHO Warns Security Issues Continue To Hinder Response; J&J Files For European Approval Of Ebola Vaccine

CIDRAP News: DRC Ebola cases hit 3,285 as transmission rate slows
“From Oct. 28 to Nov. 3, only 10 new Ebola cases from five health zones were confirmed in the Democratic Republic of the Congo (DRC), but the World Health Organization (WHO) warns that security issues and poor access continue to hinder the response in rural hot spots. In research findings, a study [Wednesday] highlighted serious long-term symptoms among Ebola survivors…” (Soucheray, 11/6).

Reuters: Johnson & Johnson files for European approval of Ebola vaccine
“Johnson & Johnson said on Thursday it had filed for an approval from European regulators for its two-dose experimental vaccine to protect against Ebola, less than a month after the agency recommended approval of Merck & Co Inc’s vaccine. J&J said it submitted two marketing authorization applications to the European Medicines Agency (EMA) for its vaccine regimen targeting the Zaire strain of the Ebola virus, which most commonly causes outbreaks of the deadly disease…” (Mathias, 11/7).

Additional coverage of how Ebola survivors are assisting in care of patients in DRC is available from Christian Science Monitor.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.